Cramer says SolarCity is too hard for him and he's losing patience with Cigna.
With interest rate hikes this year a distinct possibility, the big money managers are springing into action, Cramer says. Here's what to buy.
Impax (IPXL) reported lower-than-anticipated earnings and revenue for the 2016 second quarter and a downbeat forecast before Tuesday's market open.
The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.